Autologous and Donor-derived CD7 CAR-T Therapy(Beijing GoBroad Hospital)

N/A

Report date: 2024/03/22 20:01:55

Base Information

Drug NameAutologous and Donor-derived CD7 CAR-T Therapy(Beijing GoBroad Hospital)
Drug Alias NameAutologous and Donor-derived CD7 CAR T-cell Therapy(Beijing GoBroad Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsT-cell antigen CD7 modulators
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing GoBroad Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBeijing GoBroad Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A